NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Donahue KE, Gartlehner G, Schulman ER, et al. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. (Comparative Effectiveness Review, No. 211.)
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].
Show details| Abbreviation or Acronym | Meaning |
|---|---|
| ABAa | abatacept |
| ACR | American College of Rheumatology (20/50/70 = 20%/50%/70% improvement) |
| ADAb | adalimumab |
| AE(s) | adverse event(s) (S = serious) |
| AGREE | Abatacept trial to Gauge Remission and joint damage progression in methotrexate-naïve patients with Early Erosive rheumatoid arthritis |
| AHRQ | Agency for Healthcare Research and Quality |
| ALT | alanine transaminase |
| ASPIRE | Active-controlled Study of Patients receiving Infliximab for the treatment of Rheumatoid arthritis of Early onset trial |
| AST | aspartate aminotransferase |
| AVERT | Assessing Very Early Rheumatoid arthritis Treatment trial |
| Avg | average |
| BARFOT | Better Anti Rheumatic FarmacOTherapy trial |
| BeSt | Dutch acronym for Behandel-Strategieen, ïtreatment strategiesï trial |
| biwkly | biweekly |
| BMI | body mass index |
| BRAF-MDQ | Bristol Rheumatoid Arthritis Fatigue ï Multidimensional Questionnaire |
| C-OPERA | Certolizumab-Optimal Prevention of joint damage for Early RA trial |
| CAMERA-II | Computer Assisted Management in Early Rheumatoid Arthritis trial-II |
| CARDERA | Combination Anti-Rheumatic Drugs in Early Rheumatoid Arthritis trial |
| CareRA | Care for Early RA trial |
| CCP | cyclic citrullinated peptide |
| COBRA | Dutch acronym for Combinatietherapie Bij Reumatoide Artritis trial |
| combo | combination therapy |
| COMET | Combination of Methotrexate and Etanercept in Active Early Rheumatoid Arthritis trial |
| CQ | Contextual Question |
| CRP | C-reactive protein |
| CS | corticosteroid(s) |
| csDMARD | conventional synthetic DMARD |
| CZPb | certolizumab pegol |
| D | day(s) |
| d/c | discontinuation |
| DAS | Disease Activity Score (based on 44 joints) |
| DAS28 | Disease Activity Score in 28 joints (ïï-ESR = using ESR; ïï-CRP = using CRP) |
| DAS28-4 ESR | Disease Activity Score in 28 joints with 4 variables including ESR |
| DMARD | disease modifying antirheumatic drug |
| Enbrel ERA | Enbrel Early RA trial |
| EPC | Evidence-based Practice Center |
| ESR | erythrocyte sedimentation rate |
| ETNb | etanercept |
| EULAR | European League against Rheumatism |
| EQ-5D or EuroQoL | European Quality of Life Questionnaire-5 Dimensions |
| EuroQOL VAS | European Quality of Life Visual Analogue Scale |
| FDA | U.S. Food and Drug Administration |
| FIN-RACo | Finnish Rheumatoid Arthritis Combination Therapy trial |
| FUNCTION | trial whose acronym not described |
| G1, 2… | group 1, 2… |
| g/day | grams per day |
| GC | glucocorticoid |
| GI | gastrointestinal |
| GOLb | golimumab |
| GUEPARD | French acronym for Guerir la PolyArthrite Rhumatoide Debutante [cure early RA] trial |
| HAQ | Health Assessment Questionnaire |
| HAQ-DI | Disability Index of the Heath Assessment Questionnaire (HAQ) |
| HCQc | hydroxychloroquine |
| HIT HARD | High Induction Therapy with Anti-Rheumatic Drugs trial |
| HOPEFUL 1 | Human anti-TNF monoclonal antibody Outcome study for the Persistent EFficacy Under aLlocation to treatment strategies in early RA |
| HR | hazard ratio |
| HRQOL | health related quality of life |
| i.m. | intramuscular |
| IDEA | Infliximab as Induction Therapy in Early Rheumatoid Arthritis trial |
| IFXb | infliximab |
| IMAGE | International study in Methotrexate-Naïve Patients Investigating Rituximabïs Efficacy |
| IMPROVED | Induction therapy with Methotrexate and Prednisone in Rheumatoid or Very Early arthritic Disease trial |
| IQR | interquartile range |
| ITT | intention to treat |
| IV | intravenous |
| Kg | kilograms |
| KQ | Key Question |
| LEFc | leflunomide |
| Max | maximum |
| Methyl-PNLd | methylprednisolone |
| mg | milligrams |
| MHC | major histocompatibility complex |
| mos | months |
| MRI | magnetic resonance imaging |
| mTSS | Modified Sharp/van der Heijde Method for Scoring Radiographs score |
| MTXc | methotrexate |
| N | number |
| NA | not applicable |
| NEO-RACo | New Finnish RA Combination Therapy trial |
| NOR-DMARD | Norwegian Antirheumatic Drug Register |
| NR | not reported |
| nRCT | nonrandomized controlled trial |
| NS | not significant |
| NWMA | network meta-analysis(es) |
| OPERA | OPtimized treatment algorithm in Early RA |
| OPTIMA | Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab trial |
| OR | odds ratio |
| ORBIT | Optimal Management of patients with rheumatoid arthritis who Require Biologic Therapy trial |
| PCORI | Patient-Centered Outcomes Research Institute |
| PICOTS | population, intervention/exposure, comparator, outcomes, time frames, country and clinical settings, and study design |
| PNLd | prednisolone |
| PREDd | prednisone |
| PREMIER | trial whose acronym not described |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| PRO | patient-reported outcome |
| PROSPERO | International Prospective Register of Systematic Reviews |
| PROWD | PRevention of Work Disability trial |
| pt-years | patient-years |
| QOL | quality of life |
| RCT | randomized controlled trial |
| RA | rheumatoid arthritis |
| RCT | randomized controlled trial |
| RF | rheumatoid factor |
| RITa | rituximab |
| ROB | Risk of bias |
| RR | risk ratio |
| SARa | sarilumab |
| SD | standard deviation |
| SE | standard error |
| SF-12 | Short Form Survey (MCS = Mental Component Score; PCS = Physical Component Score) |
| SF-36 | Short Form 36 Health Survey (MCS = Mental Component Score; PCS = Physical Component Score) |
| SHS | Sharp/van der Heijde Method for Scoring Radiographs |
| SIR | standardized incidence ratio |
| SMD | standardized mean difference |
| SOE | strength of evidence |
| SR | systematic review |
| SSZc | sulfasalazine |
| SWEFOT | Swedish Pharmacotherapy Study |
| TB | tuberculosis |
| TCZa | tocilizumab |
| TEAR | Treatment of Early Aggressive Rheumatoid Arthritis Trial |
| TNF | tumor necrosis factor |
| TOFe | tofacitinib |
| tREACH | treatment in the Rotterdam Early Arthritis Cohort trial |
| tsDMARD | targeted synthetic DMARD |
| TSU | tight step-up |
| U-Act-Early | trial whose acronym not described |
| ULN | upper limit of normal |
| URTI | upper respiratory tract infection |
| UTI | urinary tract infection |
| VAS | visual analogue scale |
| vs. | versus |
| WPS-RA | Work Productivity Survey - Rheumatoid Arthritis |
| yrs | years |
| 95% CI | 95% confidence interval |
- a
Non-TNF Biologics
- b
TNF Biologics
- c
csDMARDs
- d
Corticosteroids
- e
tsDMARDs
- Abbreviations and Acronyms - Drug Therapy for Early Rheumatoid Arthritis: A Syst...Abbreviations and Acronyms - Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update
- Introduction - Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review ...Introduction - Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update
Your browsing activity is empty.
Activity recording is turned off.
See more...